FOG-001 in Locally Advanced or Metastatic Solid Tumors
Cancer · Colorectal Cancer · Solid Tumor · Locally Advanced Solid Tumor · Metastatic Cancer · WNT Pathway · HCC · Desmoid · Microsatellite Stable Colorectal Cancer · Metastatic Castration-resistant Prostate Cancer · Familial Adenomatous Polyposis (FAP) · Endometrial Carcinoma · Prostate Cancer · Microsatellite Instability-High Colorectal Cancer · Adamantinomatous Craniopharyngioma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 619 (planned)
- Started
- May 23, 2023
- Main results expected
- Apr 1, 2027
- Fully finished
- Aug 31, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
During dose escalation and dose expansion measure incidence and severity of treatment emergent adverse events by CTCAE v5.0
Measured over: Through study completion, an average of 10 months
During dose escalation characterize dose-limiting toxicities (DLTs)
Measured over: 1 treatment cycle (28 days)
During dose expansion describe the Overall Response Rate using RECIST v1.1
Measured over: Every 63 days until study completion, approximately 10 months on average
During dose expansion describe the Disease Control Rate using RECIST v1.1 (Part 2a only)
Measured over: 4 months
During dose expansion describe the PSA30 response rate for participants with prostate cancer
Measured over: Baseline, weekly during the first 2 cycles (56 days), bi-weekly during the Cycle 3 (28 days), and then monthly (up to approximately 7 months)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05919264 · record last updated 2026-10-07 · checked 2026-11-09 15:36 UTC